ConserV Bioscience publishes NK-cell activation by FLU-V antibodies in Vaccines
FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans. […]
A new paper published in Vaccines: “AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to Aedes Mosquito Bites in Humans”
AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to Aedes Mosquito Bites in Humans. […]
Influenza Research Consortium Announces £1.2 million (C$2.2 million) in Funding for the Development of a Novel Broad-Spectrum Influenza Vaccine.
London, United Kingdom. July 7th, 2025 ConserV Bioscience Limited, 4basebio plc, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) announce that the UK and Canadian governments are providing up to a combined £1.2 million (C$2.2 million) in funding to develop and manufacture a broadly protective influenza vaccine. This project is supported through the Canada-UK 2024-25 collaborative industrial R&D call for proposals on enabling technologies and innovations for biomanufacturing of biologics and advanced therapeutics. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP). Over two years, the new collaboration will employ next generation nucleic acid vaccine and delivery technologies, developed by 4Basebio and Pegasus Biotech, to combine seasonal influenza vaccines with…Read More […]
Project to improve global flavivirus defence kicks off
[Jan 2024] ConserV Bioscience Limited joins the FLAVIVACCINE consortium, aiming to develop a vaccine against mosquito-borne flaviviruses such as Dengue, West Nile and Yellow Fever viruses. […]
ConserV Bioscience pan-coronavirus project has been awarded UK Aid funding by the UK Vaccine Network by Innovate UK
[Jan 2024] ConserV Bioscience Limited, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, has been awarded UK Aid funding to advance development of its pan-coronavirus vaccine candidate, UNICOR-v. UNICOR-v aims to protect against all coronaviruses including those from alpha, beta, delta and gamma genera. […]
ConserV Bioscience in collaboration with Walter Reed Army Institute of Research awarded a grant by CDMRP to evaluate a novel malaria vaccine candidate
[Jan 2024] ConserV Bioscience Limited, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, has been awarded a grant under the Peer Reviewed Medical Research Program (PRMRP) of the Congressionally Directed Medical Research Programs (CDMRP) for the evaluation of a novel malaria vaccine candidate in collaboration with Walter Reed Army Institute of Research. […]
ConserV Bioscience ARBO-SAL project has been awarded UK Aid funding by the UK Vaccine Network, delivered by Innovate UK
[Jan 2024] ConserV Bioscience Limited, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, has been awarded funding by the Department of Health and Social Care as part of the UK Vaccine Network to advance development of its arbovirus vaccine platform, ARBO-SAL. […]
ConserV Bioscience pan-coronavirus project has been awarded UK Aid funding by the UK Vaccine Network, delivered by Innovate UK
ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, has been awarded UK Aid funding to advance development of its pan-coronavirus vaccine candidate, UNICOR-v. […]
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases
LONDON and NIEL, Belgium, March 4, 2021 /PRNewswire/ — ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA immunotherapies NV (“eTheRNA”), a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its ground-breaking TriMix technology, have agreed to collaborate on the development of vaccine candidates for infectious diseases. It is anticipated that by combining ConserV’s and eTheRNA’s technologies, the new vaccines will induce potent immune responses to protect against highly mutagenic viruses. […]
ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine
London, United Kingdom and Livermore, California, January 19, 2021 – ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and Lawrence Livermore National Laboratory (“LLNL”) have agreed to collaborate on the development of a broad-spectrum coronavirus vaccine. […]